Drug Profile
Tarafenacin
Alternative Names: SVT-40776Latest Information Update: 30 Jul 2015
Price :
$50
*
At a glance
- Originator SALVAT
- Developer Kwang Dong Pharmaceutical; SALVAT
- Class Antispasmodics; Quinuclidines
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Overactive bladder
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 30 Jul 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, Australia, Czech Republic, Germany, Hungary, Netherlands, New Zealand, Russia, South Africa, South Korea and Spain (PO)
- 09 Apr 2013 Efficacy and adverse events data from a phase IIb trial in Overactive bladder in South Korea released by SALVAT and Kwang Dong
- 09 Apr 2013 SALVAT and Kwang Dong complete a phase IIb trial in Overactive bladder in South Korea (NCT01458197)